Abstract
The increasing costs of health care, including new
technologies and pharmaceuticals, pose challenges
for all countries both in the developed and
the developing world. It is essential that the
increased expenditure on pharmaceuticals represents
value for money and is seen as an investment
in health care rather than simply the purchase of
the latest released agent. The system in Australia
uses a cost-effectiveness approach to guide the
decisions as to whether a new drug can be recommended
for subsidy. The need for a greater understanding
and transparency of the processes is
essential in order for a well-informed public debate
to occur about the challenges to the system and its
sustainability. The relevant issues are discussed in
this article to assist that debate.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献